NCT06294288View on ClinicalTrials.gov

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

September 3, 2023

Study Completion Date

March 15, 2024

Conditions
Chronic Spontaneous Urticaria
Interventions
BIOLOGICAL

LP-003 Dose 1 (Single)

A single dose of LP-003 (Dose 1) was administered intravenously.

BIOLOGICAL

LP-003 Dose 2 (Single)

A single dose of LP-003 (Dose 2) was administered intravenously.

BIOLOGICAL

LP-003 Dose 3 (Single)

A single dose of LP-003 (Dose 3) was administered intravenously.

BIOLOGICAL

LP-003 Dose 4 (Single)

A single dose of LP-003 (Dose 4) was administered intravenously.

BIOLOGICAL

LP-003 Dose 5 (Single)

A single dose of LP-003 (Dose 5) was administered intravenously.

BIOLOGICAL

Placebo (Single)

A single dose of placebo was administered intravenously.

BIOLOGICAL

LP-003 Dose 6 (Multiple)

LP-003 (Dose 6) was administered multiple times subcutaneously.

BIOLOGICAL

LP-003 Dose 7 (Multiple)

LP-003 (Dose 7) was administered multiple times subcutaneously.

BIOLOGICAL

LP-003 Dose 8 (Multiple)

LP-003 (Dose 8) was administered multiple times subcutaneously.

BIOLOGICAL

Placebo (Multiple)

Placebo was administered multiple times subcutaneously.

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

Sponsors

Lead Sponsor

Longbio Pharma
All Listed Sponsors
lead

Longbio Pharma

INDUSTRY